We founded atai Impact to support and collaborate with nonprofits and organisations that share our vision.
Co-founder, and Chief Executive Officer
Srinivas is a Co-founder of atai and served as Chief Scientific Officer for five years before becoming Co-Chief Executive in 2024 and Chief Executive in 2025. He refers to himself as being an engineer at heart and credits this mindset for his passion in seeking to understand the brain, particularly as it regards mental health disorders.
With more than two decades of experience in the pharmaceutical industry, he has held the titles of Chief Scientific, Medical and Executive at multiple companies ranging from venture-backed startups to vertically integrated, publicly traded pharmaceutical companies.
Srini completed his internship in Internal Medicine at Yale-New Haven Hospital. He received his medical degree from Yale School of Medicine and holds a Ph.D. in Neurobiology and a Master of Science in Electrical Engineering from Yale Graduate School.
Srinivas Rao, M.D., Ph.D.
Chief Financial Officer
Anne became Chief Financial Officer in 2024, previously serving as Chief Accounting Officer and Vice President of Finance and Global Controller since joining atai in 2022. She oversees finance, accounting, financial planning & analysis, tax and treasury and investor relations.
With more than three decades in corporate finance, Anne has held multiple leadership positions, drove four IPOs and other major financing transactions. She has spent most of her career in the life sciences sector and has a deep personal connection to mental health.
Anne is a Certified Public Accountant (CPA) and a Chartered Management Accountant (CGMA) and holds a B.Sc in Accounting from the University of North Carolina at Wilmington.
Anne Johnson
Chief Medical Officer
Kevin became Chief Medical Officer in 2025, previously serving as Senior Vice President of Clinical Development since 2021. He is responsible for developing and driving the execution of clinical development, regulatory affairs, drug safety, and biostatistics.
Kevin has over 20 years of clinical experience and has spent the past decade leading global medical teams, and clinical development in neuroscience pipelines. Before joining the industry, Kevin held a faculty appointment at the Behavioural and Clinical Neuroscience Institute at the University of Cambridge and has published widely on the cognition and brain imaging in mental health. He began his industry career at P1vital, developing imaging and cognitive biomarkers to enhance decision-making for early-phase psychiatry trials.
He received his medical degree from the University of Witwatersrand, South Africa, and holds a MPhil in Medical Science from the University of Cambridge. He is a member of the Royal Collage of Psychiatrists and holds and specialist accreditation in addiction and adult psychiatry.
Kevin Craig, M.D.
Chief Business Officer
Sahil has extensive expertise in building bio-pharma pipelines and executing commercial strategies. He joined the atai leadership team in 2022. He leads the portfolio strategy, business development, early commercialization, and corporate communication functions.
Previously, Sahil held multiple senior leadership positions at Otsuka Pharmaceutical Co., Ltd. for over eight years, where he built a successful pipeline in CNS, nephrology and oncology, closed more than USD 2.7 billion in transactions and worked on the successful commercial launch of multiple drugs. Throughout his career he has worked across geographies and markets in large and small companies – setting up teams and offices across the world, including London, Singapore, and Shanghai.
He is a trained physician and holds an MPhil from the University of Cambridge (where he is subsequently an honorary lecturer).
Sahil Kirpeker, M.D.
Chief Scientific Officer
Glenn became Chief Scientific Officer in 2025, previously serving as Senior Vice President of Early Development since 2022. He leads internal innovation, overseeing early-stage product development and integrating translational medicine into development, and clinical strategies.
Glenn has over twenty years of industry and research experience and has been involved in numerous programs that leverage cutting-edge biotechnologies to develop new therapies to address unmet medical needs. He has held multiple senior leadership positions in both venture-backed startup and public companies using his expertise and passion to help drive R&D programs to meaningful proof-of-concept and value-inflection.
Glenn received his Ph.D. in Chemistry from the University of Virginia and conducted his postdoctoral training in Molecular Biology at Massachusetts General Hospital/Harvard Medical School in Boston.
Glenn Short, Ph.D.
Chief Operating Officer
Gerd joined atai as Chief Operating Officer in 2024, bringing over 25 years of experience in leadership roles across the pharmaceutical and biotech sectors. He has a strong track record in drug development, corporate development, and team leadership. Gerd leads atai’s development and business operations, and quality infrastructure.
Before atai, Gerd was COO at NFlection Therapeutics and Senior VP of Operations at PellePharm, a BridgeBio company. He also held leadership positions at Depomed, FibroGen, and Gryphon Therapeutics.
Gerd holds a Ph.D. in Chemistry from UC Berkeley, is an inventor on multiple patents and has published more than 25 papers in peer-reviewed literature.
Gerd Kochendoerfer, Ph.D.
General Council
Ryan joined atai in August 2020. As General Counsel, he oversees atai’s legal, compliance and IP functions.
For more than a decade, Ryan has served on the executive teams of public and private biotechnology companies where he was responsible for building and leading the legal, corporate development, and intellectual property functions.
Ryan is an attorney admitted to the bar of the Commonwealth of Massachusetts. He received his Juris Doctor (JD) from Case Western Reserve University School of Law and holds a B.S. in biochemistry and a B.A. in Italian language from Trinity College.
Co-Founder and Chairman
Christian Angermayer is a serial entrepreneur and investor who builds and invests in companies that are shaping the Next Human Agenda: a future in which technology empowers people to live longer, healthier, and happier lives. He is the world’s leading advocate for human enhancement and believes in advancing scientific progress to usher in an era of physical and mental potential, improving life for all.
Apeiron Investment Group, Christian’s family office and private investment firm, has more than USD 2.5 billion under management and 50 people in London, New York City, Abu Dhabi and Berlin. Apeiron focuses on Life Sciences, FinTech & Crypto, Future Tech, Natural Resources & Clean Energy, and Experiences, Hospitality & Happiness. Over the past 20 years, Christian has founded three unicorns and has been the lead investor in four unicorns and two decacorns.
Christian’s current areas of focus include:
Christian is recognized for leading the current psychedelics renaissance which he believes will end the global mental health crisis. atai Life Sciences (Nasdaq: ATAI), founded by Christian, is developing psychedelic compounds including psilocybin, ketamine, DMT, and ibogaine, and their potential use as approved medical treatments.
He has founded two biotech companies, Rejuveron Life Sciences and Cambrian Biopharma, that are developing medical drugs with the aim to significantly prolong the human life and health span. He is also a sponsor of the XPRIZE Healthspan, the $101 million competition that will incentivize new therapeutics to improve healthy aging and close the gap between life and health expectancy.
Christian is also a driving force behind the world’s leading BCI developer, Blackrock Neurotech. The Utah-based company is developing innovative brain technologies provide new hope for people with paralysis and other neurological disorders – and already has almost 50 BCIs implanted in patients’ brains.
Christian Angermayer
Director
Audit Committee, Chair
Nominating and Corporate Governance Committee, Chair
Sabrina is a life sciences executive with a strong track record in building successful companies, launching innovative products, and delivering shareholder value. She is the Founder and CEO of DARÉ Bioscience.
Before DARÉ, Sabrina was President of WomanCare Global Trading, CFO/CAO of the California Institute for Biomedical Research, and CFO/COO of Cypress Bioscience, Inc. She also held marketing and sales roles at Advanced Tissue Sciences and started her career as a research scientist at Baxter Healthcare.
She serves on the boards of Aethlon Medical, BIOCOM, the Clearity Foundation, and the YWCA of San Diego County, among others. Sabrina has been recognized for her contributions, including the Athena Individual in Life Science award, the “Moxie” award, and being a finalist for E&Y Entrepreneur of the Year in 2018. In 2019, she was named Director of the Year by the San Diego Corporate Directors Forum.
Sabrina holds a Master of International Management from Thunderbird, an MSc in Biochemical Engineering from University College London, and a BSc in Biomedical Engineering from Tulane University.
Sabrina Martucci Johnson
Director
Science and Technology Committee, Member
Audit Committee, Member
Amir is a globally recognized physician-scientist and innovator at the intersection of life sciences and technology. He serves as a board director and advisor to private and public companies, universities and investment groups in the life sciences and tech sectors.
Amir is Co-Chair of the Decentralized Trials and Research Alliance (DTRA) and Chairman of the CNS Summit, a forum focused on the future of life sciences. He was also the Founding Chairman of the International Society for CNS Drug Development (ISCDD) and serves on its Executive Committee.
Amir is a Professor of Psychiatry at the University of California San Diego and Editor of Innovations in Clinical Neuroscience. He has authored over 250 peer-reviewed publications and is the Lead Editor of Essential CNS Drug Development, published by Cambridge University Press. Previously, he led the Neuroscience Center of Excellence at Quintiles (now IQVIA) for nearly 20 years, where he oversaw numerous successful drug development programs. His contributions have been recognized by The Medicine Maker’s Power List and PharmaVOICE’s Red Jacket award.
Amir is a frequent speaker at scientific meetings, addressing topics like drug development, digital medicine, clinical trials, and biohacking.
Director
Compensation Committee, Chair
Nominating and Corporate Governance Committee, Member
Audit Committee, Member
Andi is a seasoned Life Sciences executive with 28 years of experience in commercialization and general management roles across public and private companies. Currently, she is the President and CEO of VMS BioMarketing, a healthcare services company focused on improving patient outcomes through technology-enabled, data-driven clinical educator platforms.
Previously, Andi spent 18 years at Eli Lilly and Company, holding leadership roles across finance, business development, corporate affairs, and brand management. She led P&L for key therapeutic areas like endocrinology, women’s health, and osteoporosis, consistently driving strong revenue growth.
Andi joined VMS in 2008 and became CEO in 2011. Under her leadership, VMS has seen double-digit growth, with strategic investments in technology and infrastructure. Her efforts have fostered an award-winning company culture recognized by Fortune and Great Place to Work.
Andi serves on the board of Rockwell Medical and advises Agent Capital. She has held board positions at Assertio Therapeutics, Zyla Life Sciences, and the Indiana Alzheimer’s Association.
Andi holds a BA in economics from DePauw University, where she was an Honors Management Fellow.
Andrea Heslin Smiley
Director
Science and Technology Committee, Chair
Audit Committee, Member
Scott is Chief Executive Officer and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operating Officer at Pacira Pharmaceuticals, Inc. and portfolio manager of the JP Morgan Global Healthcare Fund. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group, earning his medical degree from the Albert Einstein College of Medicine and his undergraduate degree from Cornell University.
Scott Braunstein, M.D.
Director
Science and Technology Committee, Member
Compensation Committee, Member
Laurent is CEO and President of Adverum Biotechnologies and serves on the Board of Directors at Mirum Pharmaceuticals, Inc., Lycia Therapeutics and Teal. Previously, he was Chairman of CTI Biopharma, CEO of Tobira Therapeutics (subsequently Allergan), and held leadership roles at Jennerex, RXCentric (now part of Allscripts Healthcare Solutions), MedVantx, Dupont Pharmaceuticals, Dupont-Merck, and F. Hoffmann-La Roche. Laurent earned an undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.
Laurent Fischer, M.D.